EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Vergleichsstudie

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

Giannis Mountzios, Longhua Sun, Byoung Chul Cho iD, Umut Demirci, Sofia Baka, Mahmut Gümüş, Antonio Lugini, Bo Zhu, Yan Yu, Ippokratis Korantzis, Ji-Youn Han, Tudor-Eliade Ciuleanu und 15 weitere

New England Journal of Medicine · 24.07.2025 · 393 (4) · 349-361

DOI: 10.1056/nejmoa2502099 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 24.07.2025. Verfasst von Giannis Mountzios und 26 weiteren Autor:innen. Beteiligte Einrichtung: Fourth Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital Center, Athens. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Lung Neoplasms, Small Cell Lung Carcinoma, Antibodies, Bispecific. Die Arbeit wurde bisher 330-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Amgen Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Tarlatamab, a bispecific delta-like ligand 3-directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer. Whether tarlatamab is more effective than chemotherapy in the treatment of patients whose small-cell lung cancer has progressed during or after initial platinum-based chemotherapy is not known. METHODS: We conducted a multinational, phase 3, open-label trial to compare tarlatamab with chemotherapy as second-line treatment in patients with small-cell lung cancer whose disease had progressed during or after platinum-based chemotherapy. Patients were randomly assigned to receive tarlatamab or chemotherapy (topotecan, lurbinectedin, or amrubicin). The primary end point was overall survival. Key secondary end points were investigator-assessed progression-free survival and patient-reported outcomes. Results of the prespecified interim analysis (data-cutoff date, January 29, 2025) are reported. RESULTS: A total of 509 patients were randomly assigned to receive tarlatamab (254 patients) or chemotherapy (255 patients). Treatment with tarlatamab resulted in significantly longer overall survival than chemotherapy (median, 13.6 months [95% confidence interval {CI}, 11.1 to not reached] vs. 8.3 months [95% CI, 7.0 to 10.2]; stratified hazard ratio for death, 0.60; 95% CI, 0.47 to 0.77; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsLung NeoplasmsSmall Cell Lung CarcinomaAntibodies, BispecificAntineoplastic Agents, ImmunologicalAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAnthracyclinesProgression-Free SurvivalTopotecanDyspneaCoughSeverity of Illness IndexDisease ProgressionTreatment OutcomeYoung AdultCarbolinesHeterocyclic Compounds, 4 or More Rings

Substanzen

AMG 757amrubicinAnthracyclinesPM 01183TopotecanAntibodies, BispecificAntineoplastic Agents, ImmunologicalCarbolinesHeterocyclic Compounds, 4 or More Rings

Autor:innen und Institutionen

  • Fourth Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital Center, Athens.
  • Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
  • Department of Medical Oncology, Memorial Ankara Hospital, Ankara, Turkey.
  • European Interbalkan Medical Center, Thessaloniki, Greece.
  • Istanbul Medeniyet University, Istanbul, Turkey.

ORCID-Profile: Byoung Chul Cho, Sally C M Lau, Charles M Rudin

Förderung

  • Amgen Inc.

Zitieren

APA

Mountzios, G., Sun, L., Cho, B. C., Demirci, U., Baka, S., Gümüş, M., Lugini, A., Zhu, B., Yu, Y., Korantzis, I., Han, J. Y., Ciuleanu, T. E., Ahn, M. J., Rocha, P., Mazières, J., Lau, S. C. M., Schuler, M., Blackhall, F., Yoshida, T., …, & DeLLphi-304 Investigators (2025). Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. New England Journal of Medicine, 393(4), 349-361. https://doi.org/10.1056/nejmoa2502099

Vancouver

Mountzios G, Sun L, Cho BC, Demirci U, Baka S, Gümüş M, et al. Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. New England Journal of Medicine. 2025;393(4):349-361. doi:10.1056/nejmoa2502099

BibTeX
@article{Mountzios2025,
  author = {Mountzios, Giannis and Sun, Longhua and Cho, Byoung Chul and Demirci, Umut and Baka, Sofia and Gümüş, Mahmut and Lugini, Antonio and Zhu, Bo and Yu, Yan and Korantzis, Ippokratis and Han, Ji-Youn and Ciuleanu, Tudor-Eliade and Ahn, Myung-Ju and Rocha, Pedro and Mazières, Julien and Lau, Sally C M and Schuler, Martin and Blackhall, Fiona and Yoshida, Tatsuya and Owonikoko, Taofeek K and Paz-Ares, Luis and Jiang, Tony and Hamidi, Ali and Gauto, Diana and Recondo, Gonzalo and Rudin, Charles M and DeLLphi-304 Investigators, DeLLphi-304 Investigators},
  title = {Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {4},
  pages = {349--361},
  doi = {10.1056/nejmoa2502099}
}
Kostenlos starten →